Neoplasms, Squamous Cell

肿瘤,鳞状细胞
  • 文章类型: Journal Article
    染色体不稳定(CIN)和非整倍性是癌症的标志。CIN定义为在多个细胞分裂过程中染色体不分离事件的连续速率。CIN导致非整倍性,染色体含量异常的状态,与单倍体的倍数不同。人乳头瘤病毒(HPV)是口咽鳞状细胞癌的众所周知的原因,子宫颈,还有肛门.HPVE6和E7癌基因在癌变过程中具有众所周知的作用,但是额外的基因组事件,如CIN和非整倍性,通常是肿瘤形成所必需的。HPV+鳞状细胞癌的特定类型CIN的频率增加,包括极性染色体.CIN导致HPV+癌症特异性的染色体得失(非整倍体),与HPV癌症不同。HPV特异性CIN和非整倍性可能对预后和治疗反应有影响,并可能提供新的治疗漏洞的见解。这里,我们回顾了HPV特异性CIN类型和鳞状癌的非整倍体模式,以及这如何影响患者的预后和治疗。
    Chromosomal instability (CIN) and aneuploidy are hallmarks of cancer. CIN is defined as a continuous rate of chromosome missegregation events over the course of multiple cell divisions. CIN causes aneuploidy, a state of abnormal chromosome content differing from a multiple of the haploid. Human papillomavirus (HPV) is a well-known cause of squamous cancers of the oropharynx, cervix, and anus. The HPV E6 and E7 oncogenes have well-known roles in carcinogenesis, but additional genomic events, such as CIN and aneuploidy, are often required for tumor formation. HPV+ squamous cancers have an increased frequency of specific types of CIN, including polar chromosomes. CIN leads to chromosome gains and losses (aneuploidies) specific to HPV+ cancers, which are distinct from HPV- cancers. HPV-specific CIN and aneuploidy may have implications for prognosis and therapeutic response and may provide insight into novel therapeutic vulnerabilities. Here, we review HPV-specific types of CIN and patterns of aneuploidy in squamous cancers, as well as how this impacts patient prognosis and treatment.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    急性和慢性伤口的全球负担为加强伤口分类方法提供了令人信服的理由。诊断和确定最佳治疗方法的关键步骤。认识到这种需要,我们引入了一种基于深度卷积神经网络的创新多模式网络,用于将伤口分为四类:糖尿病,压力,外科,和静脉性溃疡.我们的多模式网络使用伤口图像及其相应的身体位置进行更精确的分类。我们方法的一个独特方面是结合了一个身体图系统,便于准确的伤口位置标记,改进了传统的伤口图像分类技术。我们的方法的一个显着特征是将VGG16,ResNet152和EfficientNet等模型集成在一个新颖的体系结构中。该架构包括空间和通道挤压和激励模块等元素,轴向注意,和自适应门控多层感知器,为分类提供了坚实的基础。我们的多模式网络在两个不同的数据集上进行了训练和评估,这些数据集包括相关图像和相应的位置信息。值得注意的是,我们提出的网络优于传统方法,在没有位置分类的情况下,感兴趣区域(ROI)的精度范围达到74.79-100%,73.98-100%的ROI与位置分类,整个图像分类为78.10-100%。这标志着比文献中先前报道的性能指标有了显著的提高。我们的结果表明,我们的多模式网络作为伤口图像分类的有效决策支持工具的潜力,为其在各种临床环境中的应用铺平了道路。
    The global burden of acute and chronic wounds presents a compelling case for enhancing wound classification methods, a vital step in diagnosing and determining optimal treatments. Recognizing this need, we introduce an innovative multi-modal network based on a deep convolutional neural network for categorizing wounds into four categories: diabetic, pressure, surgical, and venous ulcers. Our multi-modal network uses wound images and their corresponding body locations for more precise classification. A unique aspect of our methodology is incorporating a body map system that facilitates accurate wound location tagging, improving upon traditional wound image classification techniques. A distinctive feature of our approach is the integration of models such as VGG16, ResNet152, and EfficientNet within a novel architecture. This architecture includes elements like spatial and channel-wise Squeeze-and-Excitation modules, Axial Attention, and an Adaptive Gated Multi-Layer Perceptron, providing a robust foundation for classification. Our multi-modal network was trained and evaluated on two distinct datasets comprising relevant images and corresponding location information. Notably, our proposed network outperformed traditional methods, reaching an accuracy range of 74.79-100% for Region of Interest (ROI) without location classifications, 73.98-100% for ROI with location classifications, and 78.10-100% for whole image classifications. This marks a significant enhancement over previously reported performance metrics in the literature. Our results indicate the potential of our multi-modal network as an effective decision-support tool for wound image classification, paving the way for its application in various clinical contexts.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    表观遗传学是指在不改变DNA核苷酸序列的情况下发生基因表达变化的可逆过程。该过程目前作为治疗癌症和其他疾病的关键目标而越来越突出。许多针对表观遗传机制的药物已获得食品和药物管理局(FDA)的批准,用于多种疾病的治疗干预;许多有缺点,如适用性有限,毒性,和阻力。自2001年发现第一个蛋白水解靶向嵌合体(PROTACs)以来,对包含靶向蛋白降解(TPD)的PROTACs的研究,分子胶(MG),疏水标记(HyT),降解标签(DTAG),修剪,凋亡蛋白(IAP)依赖性蛋白擦除(SNIPER)的特异性和非遗传抑制剂,抗体-PROTACs(Ab-PROTACs),和其他基于溶酶体的策略取得了显著进展。在这次审查中,我们全面强调了超越PROTACs的小分子降解剂,可以实现表观遗传蛋白(包括含溴结构域的蛋白质相关靶标,组蛋白乙酰化/脱乙酰化相关靶标,组蛋白甲基化/去甲基化相关靶标,和其他表观遗传靶标)通过蛋白酶体或溶酶体途径。还讨论了该领域目前的困难和未来的前景,这对药物化学家在开发更有效的药物时可能是有价值的,选择性,和临床应用的药物样表观遗传药物。
    Epigenetics refers to the reversible process through which changes in gene expression occur without changing the nucleotide sequence of DNA. The process is currently gaining prominence as a pivotal objective in the treatment of cancers and other ailments. Numerous drugs that target epigenetic mechanisms have obtained approval from the Food and Drug Administration (FDA) for the therapeutic intervention of diverse diseases; many have drawbacks, such as limited applicability, toxicity, and resistance. Since the discovery of the first proteolysis-targeting chimeras (PROTACs) in 2001, studies on targeted protein degradation (TPD)-encompassing PROTACs, molecular glue (MG), hydrophobic tagging (HyT), degradation TAG (dTAG), Trim-Away, a specific and non-genetic inhibitor of apoptosis protein (IAP)-dependent protein eraser (SNIPER), antibody-PROTACs (Ab-PROTACs), and other lysosome-based strategies-have achieved remarkable progress. In this review, we comprehensively highlight the small-molecule degraders beyond PROTACs that could achieve the degradation of epigenetic proteins (including bromodomain-containing protein-related targets, histone acetylation/deacetylation-related targets, histone methylation/demethylation related targets, and other epigenetic targets) via proteasomal or lysosomal pathways. The present difficulties and forthcoming prospects in this domain are also deliberated upon, which may be valuable for medicinal chemists when developing more potent, selective, and drug-like epigenetic drugs for clinical applications.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    碳酸酐酶(CA),一种催化二氧化碳(CO2)可逆水合反应的酶,被认为是一种有前途的用于CO2还原的生物催化剂。由于其较高的热稳定性,热粘菌氨(taCA)的α-CA已成为引人注目的候选药物,工业应用的关键因素。然而,低水平的表达和不良的体外溶解度阻碍了taCA的进一步利用。最近,这些限制已经通过融合下一个标签来解决,海洋衍生的,增强蛋白质表达和溶解性的内在无序的小肽。在这项研究中,进一步研究了NEXT-taCA的溶解性和稳定性。当NEXT标签和taCA之间的接头长度缩短时,表达水平降低而不损害溶解度增强性能。NEXT标签和NT11标签之间的比较证明了NEXT标签在改善taCA的表达和溶解度方面的优越性。虽然taCA的热稳定性低于广泛设计的DvCA10,但与未标记的taCA相比,NEXT标记的taCA的长期热稳定性提高了30%,这表明增加的溶解度可以有助于酶的热稳定性。此外,探索了两种内在无序肽(Hcr和Hku标签)作为新型溶解度增强融合标签的生物勘探,证明了它们在提高taCA的表达和溶解度方面的性能。这些努力将促进taCA的实际应用,并为酶生物化学和生物工程提供工具和见解。
    Carbonic anhydrase (CA), an enzyme catalyzing the reversible hydration reaction of carbon dioxide (CO2), is considered a promising biocatalyst for CO2 reduction. The α-CA of Thermovibrio ammonificans (taCA) has emerged as a compelling candidate due to its high thermostability, a critical factor for industrial applications. However, the low-level expression and poor in vitro solubility have hampered further utilization of taCA. Recently, these limitations have been addressed through the fusion of the NEXT tag, a marine-derived, intrinsically disordered small peptide that enhances protein expression and solubility. In this study, the solubility and stability of NEXT-taCA were further investigated. When the linker length between the NEXT tag and the taCA was shortened, the expression level decreased without compromising solubility-enhancing performance. A comparison between the NEXT tag and the NT11 tag demonstrated the NEXT tag\'s superiority in improving both the expression and solubility of taCA. While the thermostability of taCA was lower than that of the extensively engineered DvCA10, the NEXT-tagged taCA exhibited a 30% improvement in long-term thermostability compared to the untagged taCA, suggesting that enhanced solubility can contribute to enzyme thermostability. Furthermore, the bioprospecting of two intrinsically disordered peptides (Hcr and Hku tags) as novel solubility-enhancing fusion tags was explored, demonstrating their performance in improving the expression and solubility of taCA. These efforts will advance the practical application of taCA and provide tools and insights for enzyme biochemistry and bioengineering.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Case Reports
    暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    生物钟是一个调节系统,周期约为24小时,在许多生理过程中产生有节奏的变化,包括线粒体活动。越来越多的证据将时间破坏与时钟基因表达中的异常功能联系起来,导致多种疾病,如癌症。褪黑激素,其生产和分泌根据明暗周期振荡,是时钟基因表达的主要调节因子。此外,褪黑素的抑癌作用与线粒体活性的增加有关。然而,生物钟基因表达之间的直接联系,线粒体活性,和褪黑素在癌症中的抗增殖作用,包括头颈部鳞状细胞癌(HNSCC),基本上是未知的。在这项研究中,我们分析了褪黑素对HNSCC细胞系(Cal-27和SCC9)的影响,用500和1000μM褪黑激素治疗。我们发现褪黑激素的抗增殖作用不是由Bmal1时钟基因介导的。此外,观察到高剂量的褪黑激素导致振荡昼夜节律基因(Per2和Sirt1)的再同步。令人惊讶的是,褪黑素对Per2和Sirt1的再同步作用并未改变线粒体呼吸活动的振荡。这些结果增加了我们对褪黑素治疗头颈部鳞状细胞癌可能的抗增殖机制的理解,并表明其抗增殖作用与时钟基因无关,但与线粒体活性直接相关。
    The circadian clock is a regulatory system, with a periodicity of approximately 24 h, which generates rhythmic changes in many physiological processes, including mitochondrial activity. Increasing evidence links chronodisruption with aberrant functionality in clock gene expression, resulting in multiple diseases such as cancer. Melatonin, whose production and secretion oscillates according to the light-dark cycle, is the principal regulator of clock gene expression. In addition, the oncostatic effects of melatonin correlate with an increase in mitochondrial activity. However, the direct links between circadian clock gene expression, mitochondrial activity, and the antiproliferative effects of melatonin in cancers, including head and neck squamous cell carcinoma (HNSCC), remain largely unknown. In this study, we analyzed the effects of melatonin on HNSCC cell lines (Cal-27 and SCC9), which were treated with 500 and 1000 µM melatonin. We found that the antiproliferative effect of melatonin is not mediated by the Bmal1 clock gene. Additionally, high doses of melatonin were observed to result in resynchronization of oscillatory circadian rhythm genes (Per2 and Sirt1). Surprisingly, the resynchronizing effect of melatonin on Per2 and Sirt1 did not produce alterations in the oscillation of mitochondrial respiratory activity. These results increase our understanding of the possible antiproliferative mechanisms in melatonin in the treatment of head and neck squamous cell carcinoma and suggest that its antiproliferative effects are independent of clock genes but are directly related to mitochondrial activity.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Multicenter Study
    目的:我们进行了一项多中心的真实世界研究,以评估非黑色素瘤皮肤癌(nMSC)在确定性或术后放疗后复发的根治性挽救性再放疗的结果。
    方法:回顾性地从5个大容量近距离放射治疗中心收集了2006年至2022年间接受nMSCs再照射治疗的患者的数据。主要终点是局部控制(LC)。次要终点包括总生存期,无进展生存期,和不良事件(AE)。在分析中使用了Kaplan-Meier估计和Cox比例风险模型。
    结果:共58例患者,中位年龄为78.4岁,先前接受过照射的nMSC在头颈部复发。大多数患有皮肤基底细胞癌(BCC;91.4%),并接受高剂量率近距离放射治疗(HDR-BT;91.4%)。最常见的部位包括鼻部(36.2%)和外耳(18.9%)。1年LC为73.1%,3年降至41.7%。再次照射的病灶大小是Cox分析中的独立预后因素(每mm;HR1.07;95%CI1.04-1.11;p<0.001)。7例(12.1%)报告3级或更严重的不良事件。
    结论:再次照射nMSCs,主要采用近距离放射治疗治疗放射治疗复发性BCC,与高复发率相关,失败的风险随着治疗病灶的大小而显著增加。重新照射可能是选择老年患者的一种选择,本地化,放疗后无法手术复发,无法实现局部控制或推迟全身治疗;然而,有必要进行前瞻性试验以确认其安全性和有效性.
    We conducted a multicentre real-world study to assess the outcomes of radical salvage re-irradiation for non-melanoma skin cancer (nMSC) recurrences following definitive or postoperative radiotherapy.
    Data on patients treated between 2006 and 2022 with re-irradiation for nMSCs were retrospectively collected from five high-volume brachytherapy centers. The primary endpoint was local control (LC). Secondary endpoints included overall survival, progression-free survival, and adverse events (AEs). The Kaplan-Meier estimator and Cox Proportional-Hazards Model were utilised in the analysis.
    A total of 58 patients with a median age of 78.4 years with recurrences of previously irradiated nMSC in the head and neck region were included in the analysis. The majority had cutaneous basal cell carcinoma (BCC; 91.4%), and were irradiated with high-dose-rate brachytherapy (HDR-BT; 91.4%). The most common locations included the nasal region (36.2%) and external ear (18.9%). The 1-year LC was 73.1% and decreased to 41.7% at three years. The size of the re-irradiated lesion was the single independent prognostic factor in Cox analysis (per mm; HR 1.07; 95% CI 1.04-1.11; p < 0.001). Grade 3 or worse AEs were reported in 7 cases (12.1%).
    Re-irradiation for nMSCs, predominantly administered with brachytherapy for radiorecurrent BCC, is associated with high recurrence rates, and the risk of failure significantly increases with the size of the treated lesion. Re-irradiation could be an option for selected elderly patients with small, localised, inoperable recurrences after RT to achieve local control or defer systemic treatment; however, prospective trials are necessary to confirm its safety and efficacy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 暂无摘要。
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

公众号